Those are good points. In addition, there’s a number of people participating in the various trials as patients with the backing of legitimate organizations, two foundations in fact. Decisions for patients and organizations to participate in trials are not made in a vacuum. Eighteen years ago, I participated in a clinical trial for a gene therapy to treat cancer. The decision to do that was well researched by me, and I also consulted with physicians that I thought had expertise. Additionally, physicians at various clinical sites must also make decisions to participate. My point is that decisions to participate by patients and care givers are not made lightly. These illnesses are serious. The fact that a clinical trial is successfully put together by recruiting patients and care givers sends messages of hope if not some amount of legitimacy. All of those participating are “gambling” so to speak that this molecule may be of some benefit when all else failed. All of this lends some amount of credibility that may lead to speculation that the molecule is worth risking a bit of an investors capital as well. Notice that some institutions and hedge funds are even stepping forward and buying relatively small amounts of AVXL shares thinking that there may be something to this particular molecule. “Let’s at least place a bet”, I suppose falls in the category of human psychology for participants and investors.
Market Data 
Markets 
AI
